Gelonghui, April 15, 丨 Huahai Pharmaceutical (600521.SH) announced that it has recently received the “Drug Registration Certificate” for englicin tablets approved and issued by the State Drug Administration. Engagliptin tablets are used to treat adult patients with type 2 diabetes and heart failure.
华海药业(600521.SH)：恩格列净片获得药品注册证书
Huahai Pharmaceutical (600521.SH): Empagliflozin tablets obtained drug registration certificate
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.